These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 24183612)

  • 1. Eniluracil plus 5-fluorouracil and leucovorin: treatment for metastatic breast cancer patients in whom capecitabine treatment rapidly failed.
    Rivera E; Chang JC; Semiglazov V; Burdaeva O; Kirby MG; Spector T
    Clin Breast Cancer; 2014 Feb; 14(1):26-30. PubMed ID: 24183612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
    Keith B; Guo XD; Zentko S; Harold N; Schuler B; Quinn M; Shapiro J; Grem JL
    Clin Cancer Res; 2002 May; 8(5):1045-50. PubMed ID: 12006517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors.
    Grem JL; Harold N; Shapiro J; Bi DQ; Quinn MG; Zentko S; Keith B; Hamilton JM; Monahan BP; Donavan S; Grollman F; Morrison G; Takimoto CH
    J Clin Oncol; 2000 Dec; 18(23):3952-63. PubMed ID: 11099325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer.
    Schilsky RL; Bukowski R; Burris H; Hochster H; O'Rourke M; Wall JG; Mani S; Bonny T; Levin J; Hohneker J
    Ann Oncol; 2000 Apr; 11(4):415-20. PubMed ID: 10847459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.
    Schilsky RL; Levin J; West WH; Wong A; Colwell B; Thirlwell MP; Ansari RH; Bell WN; White RL; Yates BB; McGuirt PV; Pazdur R
    J Clin Oncol; 2002 Mar; 20(6):1519-26. PubMed ID: 11896100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
    Schilsky RL; Hohneker J; Ratain MJ; Janisch L; Smetzer L; Lucas VS; Khor SP; Diasio R; Von Hoff DD; Burris HA
    J Clin Oncol; 1998 Apr; 16(4):1450-7. PubMed ID: 9552051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
    Meropol NJ; Niedzwiecki D; Hollis D; Schilsky RL; Mayer RJ;
    Cancer; 2001 Apr; 91(7):1256-63. PubMed ID: 11283924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer.
    Rivera E; Sutton L; Colwell B; Graham M; Frye D; Somerville M; Conklin HS; McGuirt C; Levin J; Hortobagyi GN
    J Clin Oncol; 2002 Feb; 20(4):987-93. PubMed ID: 11844821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
    Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
    Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
    Hennig IM; Naik JD; Brown S; Szubert A; Anthoney DA; Jackson DP; Melcher AM; Crawford SM; Bradley C; Brown JM; Seymour MT
    J Clin Oncol; 2008 Jul; 26(20):3411-7. PubMed ID: 18612156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral 5-FU analogues in the treatment of breast cancer.
    Bunnell CA; Winer EP
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):39-43. PubMed ID: 9830624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
    Adjei AA; Reid JM; Diasio RB; Sloan JA; Smith DA; Rubin J; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Atherton P; Ames MM; Erlichman C
    J Clin Oncol; 2002 Mar; 20(6):1683-91. PubMed ID: 11896120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
    Cunningham D; Coleman R
    Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
    Ochoa L; Hurwitz HI; Wilding G; Cohen D; Thomas JP; Schwartz G; Monroe P; Petros WP; Ertel VP; Hsieh A; Hoffman C; Drengler R; Magnum S; Rowinsky EK
    Ann Oncol; 2000 Oct; 11(10):1313-22. PubMed ID: 11106122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.
    Baker SD; Diasio RB; O'Reilly S; Lucas VS; Khor SP; Sartorius SE; Donehower RC; Grochow LB; Spector T; Hohneker JA; Rowinsky EK
    J Clin Oncol; 2000 Feb; 18(4):915-26. PubMed ID: 10673535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma.
    Rivera E; Valero V; Cristofanilli M; Frye DK; Booser DJ; Rosales MM; Hortobagyi GN
    Cancer; 2002 May; 94(9):2321-6. PubMed ID: 12015755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
    Lembersky BC; Wieand HS; Petrelli NJ; O'Connell MJ; Colangelo LH; Smith RE; Seay TE; Giguere JK; Marshall ME; Jacobs AD; Colman LK; Soran A; Yothers G; Wolmark N
    J Clin Oncol; 2006 May; 24(13):2059-64. PubMed ID: 16648506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
    Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
    Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.